UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 8, 2006
| | | |
| Biogen Idec Inc. |
| (Exact name of registrant as specified in its charter) |
| |
| | | | | |
| Delaware | | 0-19311 | | 33-0112644 |
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (I.R.S. Employer
Identification No.) |
| | | | | |
| | | |
| 14 Cambridge Center, Cambridge, Massachusetts | | 02142 |
| (Address of principal executive offices) | | (Zip Code) |
| | | |
Registrant’s telephone number, including area code: (617) 679-2000
| | | |
| Not Applicable |
| (Former name or former address, if changed since last report) |
| |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01 Other Events
On March 8, 2006, the Registrant and Elan Corporation, plc publicly disseminated a press release announcing that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration voted unanimously to recommend reintroduction of TYSABRI® (natalizumab) as a treatment for relapsing forms of multiple sclerosis. The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits
| (c) | | Exhibits. |
| |
| | | 99.1 The Registrant’s Press Release dated March 8, 2006. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | Biogen Idec Inc.
| |
| | By: | /s/ Susan H. Alexander | |
| | | Susan H. Alexander | |
| | | Executive Vice President, General Counsel | |
| |
Date: March 9, 2006
EXHIBIT INDEX
| | | |
| Exhibit Number | | Description |
| | | |
| 99.1 | | The Registrant’s Press Release dated March 8, 2006 |
